Search

To detect the level of vascular endothelial growth factor (VEGF) in bone marrow of patients with non-M3 acute leukemia (AL), and estimate its relationship with prognosis.From January 2016 to December 2019, 114 patients with AL in department of Hematology, Wuwei People's Hospital were selected as study group, and 25 healthy volunteers were enrolled as control group. The concentration of VEGF in bone marrow was detected by ELISA. The patients were divided into high and low concentration group according to the level of VEGF. The overall survival (OS) and event-free survival (EFS) were compared among different groups.The level of VEGF in patients with AL was significantly higher than that in the control group. The median OS and EFS in the low concentration group was 34.5 and 32 months, respectively, while, in the high concentration group was 30 and 26 months, respectively. The differences between the two groups were statistically significant (P=0.010). There were significant differences in OS rate (P=0.035) and EFS rate (P=0.026) between low and high concentration group. Multivariate analysis showed that high VEGF concentration was an independent risk factor affecting OS (HR=2.619, 95%CI 1.070-6.406, P=0.035) and EFS (HR=2.221, 95%CI 1.074-4.552, P=0.031) in AL patients.VEGF highly expresses in the bone marrow of patients with AL at initial diagnosis and relapse, and shows adverse effects on the prognosis.急性白血病患者骨髓VEGF高表达及其与预后的相关性分析.检测非M3型急性白血病（AL）患者的骨髓血管内皮生长因子（VEGF）水平，探讨VEGF的表达水平与预后的关系.选取2016年1月至2019年12月在武威市人民医院血液内科住院的AL患者共114例，以本课题组25名健康志愿者为对照组，用ELISA方法分别检测骨髓VEGF的浓度，依据VEGF表达水平进行分组，比较不同组间总生存期（OS）和无事件生存期（EFS）的差异.AL患者VEGF的表达水平明显高于对照组。VEGF低浓度组的中位OS和EFS分别为34.5和32个月，高浓度组分别为30和26个月，比较差异有统计学意义（P=0.010）。VEGF低浓度组与高浓度组的OS率与EFS率比较，差异均有统计学意义（P=0.035，P=0.026）。多因素分析显示，高浓度VEGF是影响患者OS（HR=2.619，95%CI 1.070-6.406，P=0.035）和EFS（HR=2.221，95%CI 1.074-4.552，P=0.031）的独立危险因素.AL患者初诊及复发时骨髓高表达VEGF，并对患者预后产生不良影响.

To explore the regulation effect of myeloid leukemia No.1 Chinese herb medicine prescription combined with chemotherapy on Th17 cells in bone marrow fluid of AML patients, so as to provide guidance for improving AML treatment effect and patients' long-term survival.Seventy patients with AML who were hospitalized in Department of Hematology, Wuwei People's Hospital from April 2017 to August 2019 were selected and enrolled in AML group, 25 healthy volunteers were selected and enrolled in control group; then according to therapeutic regimen, AML patients were divided into 2 groups: combined therapy group (myeloid leukemia NO.1 Chinese herb medicine prescription combined with chemotherapy) and non-combined therapy group (chemotherapy alone). Flow cytometry was used to detect the ratio of CD3The ratio of CD3Th17 cells expression in bone marrow of newly diagnoses and relapsed AML patients significantly increase, and decrease significantly after treatment. Myeloid leukemia No.1 Chinese herb prescription combined with chemotherapy can significantly increase the CR rate and reduce the RL rate for AML.髓白1号方联合化疗对急性髓系白血病患者骨髓中Th17细胞的调控作用研究.探索髓白1号方联合化疗对AML患者骨髓液中Th17细胞的调控作用，为提高AML患者治疗效果与长期生存提供指导.选取2017年4月- 2019年8月在武威市人民医院血液科住院的AML患者70例，并以25名健康志愿者纳入对照组；然后AML患者根据治疗方案分为联合治疗组（髓白1号方联合化疗）和非联合治疗组（单纯化疗）。采用流式细胞术检测骨髓液中CD3初诊及复发的AML患者CD3初诊及复发的AML患者骨髓中Th17细胞的表达水平明显升高，治疗后显著减低。髓白1号方联合化疗治疗AML可明显提高CR率，降低复发率.